Gastric cancer (GC) is one of the leading causes of morbidity and mortality worldwide. The onset and progression of gastric cancer are attributed to numerous triggers, these triggers may be infection of the gastric epithelium by Helicobacter pylori (H. pylori), or by Epstein-Barr virus (EBV). Both agents can establish a lifelong persistent infection in the host, leading to chronic inflammation, which also contributes to cancer development. Objective: The objective of this study is to present the status of co-infection with H. pylori and EBV and the risk of developing adenocarcinoma at an early age in the population of Grand Casablanca. In this study, 100 gastric tissue samples from patients with gastric cancer were examined for detection of H. pylori and EBV in tumor tissue using PCR techniques, and the clinical relevance was statistically analyzed. Results revealed an individual Epstein-Barr virus (EBV) infection observed in (40 %) of gastric carcinoma cases. Furthermore, the frequency of EBV infection was significantly different with intestinal and diffuse gastric cancer types [15 % vs. 85 %; <0.05]. The prevalence of individual H. pylori infections was 34 %, while the frequency of co-infection was 16 %. Moreover, no significant association was found between co-infection and sex, tumor grade, stage, and lymph node metastasis, but there was a significant association between co-infection and the age of GC patients. Thus understanding the status of co-infection could clarify the process of gastric carcinogenesis, and application of this knowledge for clinical purposes could facilitate diagnosis, risk management, and prevention.
30 June 2021 in Eurasian Journal of Medicine and Oncology
Objectives: Gastric cancer is one of the leading causes of morbidity and mortality worldwide. As in other cancers, the development and progression of gastric cancer has been attributed to many factors, including infection with Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV), genetic alterations, and epigenetic silencing due to aberrant methylation of tumor suppressor genes. The purpose of this work is to analyze the promoter methylation status of P53 (TP53) and E-cadherin (CDH1) genes and its association with EBV and H. pylori infections in the gastric cancer patients of Grand Casablanca. Methods: In this study, a total of 50 gastric cancer patients were recruited. Methylation in tumor tissues was detected by methylation-specific PCR (MSP), and the clinical relevance was statistically analyzed. Results: Results revealed a methylation of TP53 promoter observed in 36% of gastric carcinoma cases, which was significantly higher than adjacent normal tissue [p≤0.0001]. While no methylation of CDH1 promoter was observed. Furthermore, the frequency of TP53 promoter methylation was significantly different with intestinal and diffuse types of gastric cancer [22.3% vs 77.7%; <0.05]. Moreover cases with EBV infection had higher frequencies of TP53 methylation [p<0.05], while no significant correlation between H. pylori and TP53 methylation was observed. Conclusion: Thus; the present data suggest a vital role of epigenetic alteration of TP53 in the causation and development of gastric cancer, especially Epstein-Barr virus-associated gastric cancer in our population.